Gadolinium-based contrast agents: A comprehensive risk assessment. - Wikidata - awgldk - TriplyDB

Gadolinium-based contrast agents: A comprehensive risk assessment.

Gadolinium-based contrast agents: A comprehensive risk assessment.

http://www.wikidata.org/entity/Q39022872

about

[Intralabyrinthine schwannomas : Surgical management and hearing rehabilitation with cochlear implants. German version].Monitoring of small bowel Crohn's disease.Prospective comparison of biphasic contrast-enhanced CT, volume perfusion CT, and 3 Tesla MRI with diffusion-weighted imaging for insulinoma detection.When should we use contrast material in cardiac MRI?Intralabyrinthine schwannomas : Surgical management and hearing rehabilitation with cochlear implants.Brain metastases: neuroimaging.Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: what rheumatologists should know.MRI and multiple sclerosis--the evolving role of MRI in the diagnosis and management of MS: the radiologist's perspective.Contrast-enhanced ultrasound of the kidney: a single-institution experience.Relaxivity of Ferumoxytol at 1.5 T and 3.0 T.Salicylic Acid-Based Polymeric Contrast Agents for Molecular Magnetic Resonance Imaging of Prostate Cancer.Knee dGEMRIC at 7 T: comparison against 1.5 T and evaluation of T1-mapping methods.Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Arterial spin labelling MRI to measure renal perfusion: a systematic review and statement paper Use of Computed Tomography and Magnetic Resonance Imaging in Central Venous Disease

P2860

Q30313240-131CCFAD-9654-4282-9882-4952120C7E1D Q38652740-AE269DFF-6ECE-470D-88E2-6A9A093C37FE Q39248608-79A51662-ECCA-4DA4-8484-03655CCBBDE6 Q39290073-3489CB84-8535-4F00-80CD-2C0559AA8C7B Q41368533-216609F6-885C-48B1-B236-5799210227CD Q47879878-5B8AA4A0-1C7E-4C35-A75C-64EB52EBB865 Q48100395-68CAC138-700B-416A-8FAD-04E9D8C73200 Q49606221-53584ECA-3294-4EA5-85B2-2ADE7943BA39 Q50017556-9BA3D119-09EE-4BCC-96E5-8748A16730BE Q50034775-3C360304-29ED-4254-89B2-8D48870682E4 Q52672556-A84F1443-6538-4D34-8CDD-CD3A70C5D289 Q55253796-9E0EA48E-D192-4CB9-930E-A59D9D9FF13F Q55515077-9856CC47-0EF7-43BC-BB31-C2182168D6D6 Q57165535-10E9E9BB-E49D-44DB-84EB-71CB213ABD53 Q58571115-964ED2B7-F3BC-4916-9020-DE37479FD990

P2860

Gadolinium-based contrast agents: A comprehensive risk assessment.

http://www.wikidata.org/entity/Q39022872

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Gadolinium-based contrast agents: A comprehensive risk assessment.

@en

Gadolinium-based contrast agents: A comprehensive risk assessment.

@nl

type

label

Gadolinium-based contrast agents: A comprehensive risk assessment.

@en

Gadolinium-based contrast agents: A comprehensive risk assessment.

@nl

prefLabel

Gadolinium-based contrast agents: A comprehensive risk assessment.

@en

Gadolinium-based contrast agents: A comprehensive risk assessment.

@nl

P1433

Q39022872-7DF48C56-3616-46A2-BF3F-30858E3369C6

P1476

Q39022872-6BB801F5-1A38-469C-BC41-286C8515F27D

P2093

Q39022872-5003B80D-2596-4199-9B7A-B1F503D65F1A

Q39022872-A5D432BA-CF65-496C-BAF4-7139CCB3161A

Q39022872-EF9617FF-97F2-4444-90CD-909FF9B59D6F

P2860

Q39022872-021233D8-88A3-4CED-A839-784DECC43DF4

Q39022872-056BF02B-3F63-4436-9487-E3AC6379B5DE

Q39022872-09370698-2951-4446-852B-203232E15FE7

Q39022872-0A7C3DB0-A8C3-47C7-926E-BA90EA15E261

Q39022872-144C7D63-F588-4492-989A-68DCCAFB35C2

Q39022872-1BD23AA1-EEC5-432A-87FB-7194EC57EBEA

Q39022872-1C262FCF-EC6F-43EC-8BBC-48FDEE8F59B2

Q39022872-217001F7-B67D-4657-B808-3D2DD237CAC2

Q39022872-22125283-932D-44A2-9626-F61103225564

Q39022872-259976E1-C287-4FF0-A133-D243DDAAD9B8

P304

Q39022872-BCA29A62-5A9D-46CC-A332-5E929CA10103

P31

Q39022872-7A9D9728-8545-4CDD-9512-C4C1F2370B22

P356

Q39022872-BD5DAC8A-0819-417F-B154-FCDED34F9385

P433

Q39022872-74CD0AED-A085-40E6-8B16-B73588A3A34D

P478

Q39022872-00CADEDF-A181-4D7E-A0A2-E14E5BE4A63B

P50

Q39022872-F0B71D79-8B35-4351-B0B3-794B5F53B47C

P577

Q39022872-F8BDF650-425E-4835-B89C-E1A112D23C7C

P698

Q39022872-6A51064D-CE67-48BE-8C4A-1A8606BF0DC6

P356

P1433

Journal of Magnetic Resonance Imaging

P1476

Gadolinium-based contrast agents: A comprehensive risk assessment.

@en

P2093

Daniel R Ludwig

http://www.w3.org/2001/XMLSchema#string

Mustafa R Bashir

http://www.w3.org/2001/XMLSchema#string

Tyler J Fraum

http://www.w3.org/2001/XMLSchema#string

P2860

Imaging of Pregnant and Lactating Patients: Part 1, Evidence-Based Review and Recommendations

Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging

Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms

Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging

Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.

MRI contrast agents: basic chemistry and safety.

Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's Adverse Event Reporting System and review of case reports in the literature.

Benefits and risks of MRI in pregnancy.

High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material.

P304

338-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMRI.25625

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Kathryn J Fowler

P577

2017-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28083913

http://www.w3.org/2001/XMLSchema#string